Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

How Epstein-Barr Virus Drives Cancer Through Tiny RNA Molecules

Epstein-Barr virus-encoded microRNAs: central players in nasopharyngeal and gastric carcinoma pathogenesis.

PubMed2 min readAI-assisted summary
Editorial illustration for Epstein-Barr virus-encoded microRNAs: central players in nasopharyngeal and gastric carcinoma pathogenesis.
Editorial illustration

Summary

The Epstein-Barr virus is a complex pathogen that frequently infects humans. It specifically targets immune cells known as B cells, along with the epithelial cells that line our throats. To break into these targets, the virus uses special surface proteins as keys to unlock specific doors on the host cell, particularly the CD21/CR2 and HLA class II receptors.

Once the virus establishes an infection, it starts releasing tiny pieces of genetic code called microRNAs to manipulate the host cell's internal environment. One set of these instructions, the BHRF1 group, goes to work immediately. It forces the infected immune cells to rapidly multiply and prevents them from undergoing apoptosis, which is the natural self-destruct sequence cells use when they become damaged or infected.

A second set of instructions, the BART group, plays a major role in throat and stomach cancers. These viral molecules actively suppress the immune system's antiviral alarms, such as a signaling protein called CXCL-11. They also shut down caspase-3, a crucial protein that normally acts as an executioner to clear out sick cells. Researchers found that one specific viral molecule even blocks a natural tumor-suppressing gene named DAB2 in stomach cancer cells, allowing these harmful cells to completely evade cell death.

Why it matters.

While the Epstein-Barr virus is incredibly common, understanding how it forces cells to stay alive and multiply is vital for oncology research. By identifying the exact microRNAs the virus uses to hide from the immune system and promote tumor growth in the stomach and throat, scientists have uncovered potential new targets for medicine. Future therapies could theoretically be designed to block these specific viral molecules, stripping the cancer cells of their chemical defenses and allowing the body to naturally clear them.

It is important to keep in mind that this research is still in its preliminary phases. The discoveries are based entirely on early-stage laboratory models studying cells in a dish. There is currently no clinical data proving that targeting these mechanisms will result in safe or effective treatments for human patients, but mapping out these viral tricks is a crucial first step toward developing novel cancer therapies.

From the source

The story in numbers.

Capsomers in the EBV nucleocapsid
162
Main types of EBV-encoded microRNAs utilized
2
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
How Epstein-Barr Virus Drives Cancer Through Tiny RNA Molecules — Daily Strand